Spinal disc regenerative composition and method of manufacture and use

US10064896B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10064896-B2
Application numberUS-201414334318-A
CountryUS
Kind codeB2
Filing dateJul 17, 2014
Priority dateJul 17, 2014
Publication dateSep 4, 2018
Grant dateSep 4, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).

First claim

Opening claim text (preview).

What is claimed is: 1. An aqueous spinal disc regenerative composition suitable for injection, wherein the aqueous composition comprises: a hydrated composition comprising freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of: (i) providing normal human cadaveric intervertebral discs; (ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs; (iii) drying the nucleus pulposus; (iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at a low temperature into particles sized less than 400 microns; (v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); and then (vi) mixing the freeze-dried micronized nucleus pulposus with the fluid thereby producing the hydrated composition. 2. The aqueous spinal disc regenerative composition of claim 1 wherein the freeze-dried micronized nucleus pulposus provided for mixing in step (vi) is in the form of a powder. 3. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized freeze-dried nucleus pulposus has proteoglycan molecules. 4. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized freeze-dried nucleus pulposus has been dried to less than 5% moisture content prior to being rehydrated. 5. The aqueous spinal disc regenerative composition of claim 1 wherein the aqueous composition further comprises one or more of the following: stem cells, micronized amnion, platelet-rich plasma, growth factors, genetically altered cells that produce glycosaminoglycans, collagen Type 1 and glucose. 6. The aqueous spinal disc regenerative composition of claim 1 wherein the micronized material of dried nucleus pulposus has water absorbed by the proteoglycan molecules depleted from the freeze-dried nucleus pulposus. 7. An aqueous spinal disc regenerative composition suitable for injection, wherein the aqueous composition comprises: a hydrated composition comprising freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of: (i) providing normal human cadaveric intervertebral discs; (ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs; (iii) drying the nucleus pulposus; (iv) micronizing the dried nucleus pulposus by pulverizing in a cryomill at a low temperature into particles sized less than 400 microns; (v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); (vi) mixing the freeze-dried micronized nucleus pulposus with the fluid thereby producing the hydrated composition; wherein the freeze-dried micronized nucleus pulposus provided for mixing in step (vi) is in the form of a powder; and mixing one or more of stem cells that are derived from marrow, fat, blood or interspinous ligaments; micronized amnion; platelet-rich plasma; and/or growth factors encapsulated in pharmacologically active microspheres, with the powdered freeze-dried micronized nucleus pulposus prior to step (vi), or with the hydrated composition after step (vi). 8. The composition of claim 1 wherein the normal human cadaveric intervertebral discs are intervertebral discs aseptically recovered from cadaveric spine segments from T9 to LS. 9. A composition consisting of: (a) a syringe or injectable device which is capable of being inserted into a damaged disc to be treated; and (b) a hydrated composition consisting of freeze-dried micronized nucleus pulposus in a fluid, produced by a method consisting of: (i) providing normal human cadaveric intervertebral discs; (ii) separating the nucleus pulposus from the annulus fibrosus of the normal human cadaveric intervertebral discs; (iii) drying the nucleus pulposus; (iv) micronizing the dried nucleus pulposus by placing the dried material in a cryomill at low temperature and pulverizing the dried nucleus pulposus into particles sized less than 400 microns into a powder; (v) freeze-drying the nucleus pulposus, wherein said freeze-drying occurs during step (iii), between steps (iii) and (iv), and/or after step (iv); and then (vi) mixing the freeze-dried micronized nucleus pulposus with the fluid, thereby producing the hydrated composition and mixing one or more of stem cells that are derived from marrow, fat, blood or interspinous ligaments; micronized amnion; platelet-rich plasma; and/or growth factors encapsulated in pharmacologically active microspheres, with the powdered freeze-dried micronized nucleus pulposus prior to step (vi), or with the hydrated composition after step (vi); wherein the (b) hydrated composition with one or more stem cells is contained within the (a) syringe or injectable device; and wherein the (b) hydrated composition has a viscosity which permits it to flow through a cannula.

Assignees

Inventors

Classifications

  • Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells · CPC title

  • for introducing fluid filler into bone or extracting it (A61B17/7097, A61B17/8833 take precedence) · CPC title

  • Cartilage, synovial fluid · CPC title

  • Flowable or injectable implant compositions · CPC title

  • Intervertebral or spinal discs, e.g. resilient (non-disc-shaped intervertebral inflatable pockets A61F2/441; non-disc-shaped intervertebral fusion implants A61F2/4455) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10064896B2 cover?
The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can …
Who is the assignee on this patent?
Vivex Biomedical Inc
What technology area does this patent fall under?
Primary CPC classification A61K35/32. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).